Crossmark

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic <i>KRAS</i> and <i>ERBB2</i> ( <i>Her2</i> ) Driver Mutations

Crossref DOI link: https://doi.org/10.1158/2326-6066.CIR-18-0402

Published Online: 2019-06-03

Published Print: 2019-06-01

Update policy: https://doi.org/10.1158/crossmark_policy

Authors

Veatch, Joshua R.

Jesernig, Brenda L.

Kargl, Julia

Fitzgibbon, Matthew

Lee, Sylvia M.

Baik, Christina

Martins, Renato

Houghton, A. McGarry

Riddell, Stanley R.
Funding

Funding for this research was provided by:

HHS | National Institutes of HealthHHS | National Institutes of Health (NIH) (T32 T32CA009515)

HHS | National Institutes of HealthHHS | National Institutes of Health (NIH) (K12 CA076930-16A1)